CRP and hs-CRP: are they the same test?
They measure the same protein, but not the same clinical range. Standard CRP helps assess larger inflammatory responses. High-sensitivity CRP measures much lower concentrations and can refine cardiovascular risk in selected stable patients.
The quick answer
Same molecule. Different analytical sensitivity and different questions.
The liver produces C-reactive protein as part of the acute-phase response. Standard CRP is useful when inflammation may be clinically substantial. hs-CRP uses a method precise at lower values and is used mainly to refine atherosclerotic cardiovascular risk when the person is clinically stable. Neither test identifies the cause by itself.
CRP detects a response
It rises with infection, tissue injury, inflammatory disease, and many other conditions. It is sensitive but nonspecific.
hs-CRP is not a different protein
The high-sensitivity method accurately measures lower concentrations that standard assays may not characterize well.
Persistence matters
Cardiovascular interpretation requires a stable clinical state and usually more than one result; an acute infection or injury can invalidate the risk question.
The central distinctionCRP can show that inflammation is present. It cannot tell you where it is, what caused it, or whether treatment should target the number.
Side by side
Choose the assay according to the clinical question.
Reading the result
The context changes what the number can mean.
Laboratory ranges and units vary. These patterns guide questions; they are not diagnoses.
Look for a clinical syndrome
The result supports an inflammatory response but cannot distinguish bacterial infection, viral illness, autoimmune activity, tissue injury, or another cause by itself.
Possible cardiovascular risk enhancer
Current U.S. and Brazilian lipid guidance recognizes persistent hs-CRP at or above 2 mg/L as information that may refine risk.
First exclude acute inflammation
Traditional cardiovascular pathways advise reassessment when clinically stable rather than treating a high acute value as vascular risk.
Does not exclude every disease
Some localized, chronic, autoimmune, infectious, or malignant processes can occur with a normal result. Pretest probability still matters.
MERHI ONE Evidence Map
What CRP can support—and what it cannot prove.
Ratings apply to each exact statement, not to the marker in the abstract.
CRP is a sensitive but nonspecific marker of systemic inflammation.3
Its hepatic production increases after inflammatory stimuli, but similar elevations occur across infection, tissue injury, autoimmune disease, malignancy, obesity, smoking, and other states.
Standard CRP and hs-CRP measure the same protein at different analytical ranges.3,5
The high-sensitivity assay is optimized for lower concentrations and is therefore suited to low-grade cardiovascular-risk questions; it is not a separate inflammatory molecule.
Persistent hs-CRP at or above 2 mg/L can refine cardiovascular risk in selected adults.1,2
Both the 2026 U.S. guideline and the 2025 Brazilian dyslipidemia guideline treat this threshold as a risk-enhancing or aggravating factor in an overall assessment.
hs-CRP adds the most value when a cardiovascular decision remains uncertain.1,2,5
Traditional risk factors, LDL-C, blood pressure, diabetes, smoking, kidney disease, family history, and imaging when appropriate remain central. hs-CRP may reclassify some people but does not replace them.
Acute infection, injury, inflammatory flare, or strenuous exercise can invalidate hs-CRP risk interpretation.1,3,5
A transient elevation reflects the acute-phase response rather than stable residual cardiovascular risk.
JUPITER showed benefit from rosuvastatin in a selected population with hs-CRP at least 2 mg/L.6
The trial supports statin therapy in its enrolled risk context; it does not prove that lowering CRP itself is a universal treatment goal or that everyone with hs-CRP at least 2 needs the same drug.
An elevated CRP identifies the cause of inflammation or proves ‘chronic inflammation.’3
The marker has no anatomical or etiologic specificity. A single low-grade elevation may be transient and a high value can arise from many unrelated diseases.
Supplements or anti-inflammatory drugs should be used solely to normalize CRP.1,2,4
Treating a laboratory number without a defined disease or validated prevention pathway can cause adverse effects, interactions, false reassurance, and delayed diagnosis.
Two native pathways
The scientific core is shared; risk frameworks are local.
United States — 2026 ACC/AHA
- If measured, hs-CRP at or above 2 mg/L on more than one occasion can act as a risk enhancer.
- The marker is interpreted with global ASCVD risk and other risk enhancers; it does not replace established risk factors.
- Acute inflammatory states should be excluded before stable-risk interpretation.
Brazil — 2025 SBC
- The Brazilian dyslipidemia guideline considers hs-CRP at or above 2 mg/L an aggravating risk factor.
- Brazilian cardiovascular stratification and treatment categories should be used rather than importing a U.S. calculator without localization.
- PCR-us is an adjunct; clinical assessment, lipids, diabetes, blood pressure, smoking, kidney disease, and evidence of atherosclerosis remain central.
What can change the result
A repeat value is useful only when the context is also reviewed.
Recent infection or vaccination
Can transiently raise CRP and obscure cardiovascular interpretation.
Obesity and metabolic dysfunction
Often associate with low-grade elevation but do not establish one single inflammatory disease.
Smoking and periodontal disease
May contribute to persistent inflammation and deserve direct risk intervention.
Strenuous exercise or trauma
Can raise CRP temporarily through tissue stress.
Autoimmune or inflammatory disease
CRP may help monitor some conditions, but performance varies by disease and therapy.
Statins and anti-inflammatory therapies
May lower hs-CRP, but treatment decisions depend on validated indications and outcomes, not cosmetic normalization.
Common interpretation errors
One inflammatory number invites overdiagnosis.
The main danger is converting a nonspecific signal into a specific disease without evidence.
‘High CRP means bacterial infection’
It cannot reliably distinguish bacterial from viral or noninfectious inflammation by itself.
‘Normal CRP excludes autoimmune disease’
Sensitivity differs across conditions and disease phases.
‘hs-CRP diagnoses clogged arteries’
It refines risk; it does not image plaque or diagnose obstruction.
‘Every value above 2 mg/L needs treatment’
Persistence and total cardiovascular context are required.
‘More anti-inflammatory supplements are better’
Outcome benefit, safety, interactions, and indication must be demonstrated.
‘CRP is the cause’
It is primarily a marker within an inflammatory response, not a stand-alone explanation for symptoms.
Possible consequences of a wrong reading
- Unnecessary antibiotics or anti-inflammatory drugs
- Missed infection or autoimmune disease
- False cardiovascular diagnosis
- Unnecessary repeated testing
- Supplement interactions and toxicity
- False reassurance from a normal result
A practical next step
Turn a CRP result into the right question.
- 01
Confirm whether standard CRP or hs-CRP was ordered and why.
- 02
Review symptoms, acute illness, vaccination, exercise, injury, smoking, weight, medications, and prior values.
- 03
For acute-disease questions, interpret the trend with the clinical syndrome and companion tests.
- 04
For cardiovascular questions, repeat unexpected elevation when clinically stable and integrate it with global risk.
- 05
Investigate a persistent unexplained elevation rather than treating the marker itself.
Frequently asked questions
Direct answers to common questions.
Are CRP and hs-CRP the same test?+
They measure the same protein, but hs-CRP is designed to quantify lower concentrations accurately.
Does hs-CRP above 2 mg/L mean heart disease?+
No. It can enhance risk assessment when persistent, but it does not diagnose atherosclerosis.
Should I repeat an elevated hs-CRP?+
Usually when it was intended for cardiovascular risk and a transient cause is possible. The 2026 U.S. guideline specifies more than one occasion if measured.
Can obesity raise hs-CRP?+
Yes. Adiposity and metabolic dysfunction can contribute to low-grade inflammation, but the marker does not define the cause alone.
Should everyone measure hs-CRP?+
Not necessarily. It is most useful when it can change a cardiovascular prevention decision.
Can supplements lower CRP?+
Some interventions change the number, but lowering CRP is not automatically evidence of clinical benefit. Outcomes and safety matter.
Scientific sources
References are part of the reasoning—not decoration.
We prioritize current professional guidelines, official laboratory documentation, and landmark outcome evidence. Citations are attached to the claims they support.
- 01Open source ↗
ACC / AHA and partner societies · 2026
Guideline for the Management of Dyslipidemia
- 02Open source ↗
Sociedade Brasileira de Cardiologia · 2025
Brazilian Guideline on Dyslipidemias and Atherosclerosis Prevention
- 03Open source ↗
Centers for Disease Control and Prevention · NHANES laboratory method
High-Sensitivity C-Reactive Protein: Laboratory Description
- 04Open source ↗
American College of Cardiology · 2025
Inflammation in Cardiovascular Disease: Scientific Statement summary
- 05Open source ↗
ACC / AHA · 2019
Guideline on the Primary Prevention of Cardiovascular Disease
- 06Open source ↗
American College of Cardiology · JUPITER trial summary
Rosuvastatin in people with LDL-C below 130 mg/dL and hs-CRP at least 2 mg/L
Editorial record